Results for &quot;&quot;Dalteparin&quot;&quot;[mesh_terms]

Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects.

Ren Guo, Zhigang Ding, Yuanyuan Xiang, Lijin Yu, Xin Guo, Sujie Jia

Xenobiotica; the fate of foreign compounds in biological systems 2018;48(4):376-381

Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial.

Mohammad-Sadegh Farahvash, Marzieh Moradimogadam, Mohammad-Mehdi Farahvash, Shiva Mohammadzadeh, Ahmad Mirshahi

Archives of Iranian medicine 2009;11(4):418-22

Management of venous thromboembolism in patients with cancer: role of dalteparin.

Lori-Ann Linkins

Vascular health and risk management 2008;4(2):279-87

Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme.

Ekkehard Schleussner, Gabriele Kamin, Gregor Seliger, Nina Rogenhofer, Susanne Ebner, Bettina Toth, Michael Schenk, Melanie Henes, Michael K Bohlmann, Thorsten Fischer, Oana Brosteanu, Rupert Bauersachs, David Petroff

Annals of internal medicine 2015;162(9):601-9

Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.

Adrienne Heerey, Sanjeev Suri

PharmacoEconomics 2005;23(9):927-44

Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.

Joseph Heissler, Paula Abreu, Guillaume Feugère, Marc Carrier, Agnes Y Y Lee, Seth Woodruff

Journal of thrombosis and thrombolysis 2019;47(4):495-504

Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.

S Husted, A Kher

Annals of medicine 2001;32 Suppl 1():53-9

The management of thromboembolic disease in patients with central nervous system malignancies.

Mary Ann Knovich, Glenn J Lesser

Current treatment options in oncology 2005;5(6):511-7

High-dose intravenous dalteparin can be monitored effectively using standard coagulation times.

James M Wilson, Jerry Gilbert, Mary Harlan, Arthur Bracey, Paul Allison, Chad Schooley, Kathleen Pinto

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(2):127-38

Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid.

Mohammad S Farahvash, Marzieh Moradi Moghaddam, Sasan Moghimi, Shiva Mohammadzadeh

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2008;43(1):79-83

Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study.

Lan-Tao Zhang, Li-Bo Zhou, Chao-Chao Wang, Guo-Qiu Zhang, Tao Wu

BMC musculoskeletal disorders 2023;24(1):5

The epidemiology of peripheral vein complications: evaluation of the efficiency of differing methods for the maintenance of catheter patency and thrombophlebitis prevention.

Pavlos Myrianthefs, Maria Sifaki, Irini Samara, George Baltopoulos

Journal of evaluation in clinical practice 2005;11(1):85-9

Low molecular weight heparin for the prevention of deep venous thrombosis after total knee arthroplasty: A systematic review and meta-analysis.

Wei Zhu, Xi-Sheng Weng, Qing Zhou, Ze-Nan Xia

International journal of surgery (London, England) 2018;54(Pt A):265-275

Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.

Kevan R Polkinghorne, Lawrence P McMahon, Gavin J Becker

American journal of kidney diseases : the official journal of the National Kidney Foundation 2002;40(5):990-5